ReviewPatient preference and adherence2023
Advancing Digital Solutions to Overcome Longstanding Barriers in Asthma and COPD Management.
Review in Patient preference and adherence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Understanding Delivery and Engagement With a Digital Self-Management Intervention for Chronic Obstructive Pulmonary Disease Across Two Clinical Settings: Qualitative Study.JMIR human factors · 2026Article
- Engagement and Intersectionality in Digital Self-Management Interventions for Asthma and Chronic Obstructive Pulmonary Disease: Scoping Review.Journal of medical Internet research · 2026Article
- Understanding Australian healthcare provider attitudes towards smart inhalers for paediatric asthma management: a qualitative study.BMJ open · 2026Article
- Innovative Applications and Challenges of Artificial Intelligence in the Whole-Course Management of Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2026Review
- Prediction of site-specific drug deposition via dry powder inhaler using non-invasive real-time particle emission signal monitoring system.Frontiers in pharmacology · 2026Article
- NEXThalerJournal of clinical medicine · 2025Article
- Article
- Asthma and severe acute respiratory infections: a stratified analysis of mortality patterns in Brazil.BMC public health · 2025Article
- Advances in Therapeutics for Chronic Lung Diseases: From Standard Therapies to Emerging Breakthroughs.Journal of clinical medicine · 2025Review
- Validation of an AI-Powered Smart Dry Powder Inhaler (RS01X) for Asthma and COPD in a Clinical Setting.International journal of chronic obstructive pulmonary disease · 2025Article
- Perceptions Toward Using Artificial Intelligence and Technology for Asthma Attack Risk Prediction: Qualitative Exploration of Māori Views.JMIR formative research · 2024Article
- Assessment of Medication Adherence Using Mobile Applications in Chronic Obstructive Pulmonary Disease: A Scoping Review.International journal of environmental research and public health · 2024Article
- Uncovering patterns of inhaler technique and reliever use: the value of objective, personalized data from a digital inhaler.NPJ primary care respiratory medicine · 2024Article
- Relevance of individual bronchial symptoms for asthma diagnosis and control in patients with rhinitis: A MASK-air study.Clinical and translational allergy · 2024Article
- From illness management to quality of life: rethinking consumer health informatics opportunities for progressive, potentially fatal illnesses.Journal of the American Medical Informatics Association : JAMIA · 2024Article
- Personalizing Selection of Inhaled Delivery Systems in Chronic Obstructive Pulmonary Disease.Annals of the American Thoracic Society · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maintenance therapy delivered via inhaler is central to asthma and chronic obstructive pulmonary disease (COPD) management. Poor adherence to inhaled medication and errors in inhalation technique have long represented major barriers to the optimal management of these chronic conditions. Technological innovations may provide a means of overcoming these barriers. This narrative review examines ongoing advances in digital technologies relevant to asthma and COPD with the potential to inform clinical decision-making and improve patient care. Digital inhaler devices linked to mobile apps can help bring about changes in patients' behaviors and attitudes towards disease management, particularly when they build in elements of interactivity and gamification. They can also support ongoing technique education, empowering patients and helping providers maximize the value of consultations and develop effective action plans informed by insights into the patient's inhaler use patterns and their respiratory health. When combined with innovative techniques such as machine learning, digital devices have the potential to predict exacerbations and prompt pre-emptive intervention. Finally, digital devices may support an advanced precision medicine approach to respiratory disease management and help support shared decision-making. Further work is needed to increase uptake of digital devices and integrate their use into care pathways before their full potential in personalized asthma and COPD management can be realized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.